Thrombotic Venous Diseases of the Liver

Timothy P. Sabol¹, Marco Molina² and George Y. Wu*³

¹Department of Graduate Medical Education, Eastern Connecticut Health Network, Manchester Memorial Hospital, Manchester, CT, USA; ²Department of Radiology, University of Connecticut Health Center, Farmington, CT, USA; ³Department of Medicine, Division of Gastroenterology-Hepatology, University of Connecticut Health Center, Farmington, CT, USA

Abstract

Thrombotic venous diseases of the liver do not occur frequently, but when they do, they can present as difficult diagnostic and therapeutic challenges. The aim of this article is to review the epidemiology, pathogenesis, diagnosis, and therapeutic options of these serious vascular problems. © 2015 The Second Affiliated Hospital of Chongqing Medical University. Published by XIA & HE Publishing Ltd. All rights reserved.

Portal vein thrombosis (PVT)

PVT is an obstruction of blood flow into the liver. It is a rare vascular disorder of the liver, with an estimated incidence of 4/1,000,000 per year and a prevalence of approximately 1% in the general population.¹

The development of PVT is frequently due to a combination of local and systemic risk factors, which predispose patients to develop these disorders. Patients with PVT may present with a number of clinical symptoms.

Presentation

PVT can be subdivided into two types, acute and chronic. Symptoms in acute PVT develop within 60 days and include nausea, vomiting, diarrhea, loss of appetite, and abdominal pain. In addition, patients may present with fever, hematemesis, ascites, splenomegaly, melena, and hematochezia.² Ascites tends to occur less frequently in presinusoidal thrombosis²,³ and is more commonly the result of venous congestion.² PVT may be severe enough to lead to bowel infarction because of portal hypertension.³,⁴ Acute PVT can have a variable disease onset and clinical course (Table 1).³ Due to its rapid onset, there usually is no radiologic evidence of collateral circulation or portal hypertension in acute PVT.⁵

In contrast, patients with chronic PVT may be asymptomatic or have symptoms of jaundice, abdominal pain, cholangitis, hypersplenism, ascites, portal hypertension, variceal bleeding, and venous collateral circulation. By definition, the symptoms in the chronic condition develop over more than 60 days.⁵

Risk factors

PVT has been linked with preexisting myeloproliferative disorders.² One study found that primary myeloproliferative disorders were a major contributing factor in PVT.⁶ In these disorders, the most common mutation in cell signaling involves activation of tyrosine kinases, which results in narrow progenitor proliferation that is independent of growth factors and outside of typical cell growth control mechanisms. Since cell differentiation is not affected, proliferation of one or more mature blood elements occurs. Polycythemia vera, essential thrombocythemia, and primary myelofibrosis are the most frequent causes of PVT, likely via the Janus activated kinase 2 (JAK2) pathway.² In these cases of myeloproliferative disorders, the need for hematopoietic growth factors or erythropoietin is decreased due to stimulation of the JAK2 signaling pathway. In turn, hematocrit and red cell mass increase, which then cause decreased circulation and thrombotic events due to hyperviscosity. This may affect portal venous circulation. Late myeloproliferative disease may be associated with marrow fibrosis and compensatory enlargement of the liver and spleen secondary to extramedullary hematopoesis. Increased platelet size has also been noted, which may impair function and increase bleeding risk. Patients with this disorder may have increased risk for both thrombosis and bleeding, as described previously.³

Other risk factors of PVT are associated with antiphospholipid syndrome, and these include hereditary protein C deficiency, factor V Leiden,⁴,⁶,⁷ prothrombin G20210A,⁷ and protein S deficiency. Single or multiple prothrombotic disorders or local abnormalities within the venous structures that create turbulence from blood flow may also contribute to PVT.⁵

Recently, the V617F mutation in JAK2 was found in a significant percentage of patients with myeloproliferative disorders,⁷,⁸,⁹ and this mutation was identified as one of the major predisposing factors associated with the development of PVT. This mutation seems to affect hematopoietic stem cells, leading to the development of a myeloproliferative disorder and subsequent low flow states.⁸

In another recent study, Smalberg et al. demonstrated a link between the 46/1 haplotype and both JAK2V617F-positive splanchic vein thrombosis and JAK2V617F-negative splanchic vein thrombosis with myeloproliferative neoplasms (MPN).¹⁰ The 46/1 haplotype was not found in patients who did not have a myeloproliferative disorder. The
The study recommended screening JAK2V617F in patients with splanchnic vein thrombosis in the background of SVT-related MPN. Patients with MPN should be evaluated for the 46/1 haplotype despite being JAK2-negative because the 46/1 haplotype may confer a favorable outcome for SVT in these patients. In Western countries and in China, the literature appears to agree that JAK2V617F testing should be routinely performed in patients with noncirrhotic and nonmalignant PVT. In China, however, it is generally unnecessary to investigate JAK2V617F mutations in PVT with cirrhosis because decreased velocity of portal flow is the most likely etiology underlying PVT.

In patients with PVT and liver cirrhosis, decreased portal flow and changes in the structural components of the liver are the primary pathogenetic factors. However, as in the case of noncirrhotic patients, inherited, acquired, and local thrombophilic factors may contribute to the clinical presentation. The fibrinolysis, coagulation, and anticoagulation pathways can be affected in patients with liver cirrhosis. One study found an association between decreased levels of protein C, protein S, and an increase in D-dimer and the development of PVT in patients with liver cirrhosis. More recent studies have indicated that natural anticoagulants did not appear to have a role in the development of PVT in liver cirrhosis, particularly when the influence of liver function was removed. The severity of cirrhosis did appear to be correlated with an imbalance in coagulation factors. Comonitant PVT and liver cirrhosis is frequently associated with the presence of hepatocellular carcinoma and poor outcomes. Decreased hepatic function and tumor spread throughout the liver can contribute to poor prognosis.

### Diagnosis

Doppler ultrasound, magnetic resonance imaging (MRI), and computed tomography (CT) are frequently used imaging techniques to assist in the diagnosis of PVT. Doppler ultrasound is the first line imaging modality used due to its general availability, low cost, and lack of ionizing radiation. The lumen of the portal vein can usually be easily visualized. Doppler imaging has the added benefit of determining the presence and direction of blood flow within vessels. In PVT, grey-scale ultrasound demonstrates intraluminal hyperechoic thrombus, often distending the vein (Fig. 1A). Color doppler or power doppler will demonstrate lack of color flow in an occluded portal vein (Fig. 1B). Spectral doppler waveforms will be unobtainable in bland thrombus. If color and spectral doppler flow is present within the thrombus, malignant thrombus would be considered. Chronic PVT manifest as multiple collateral vessels (cavernous transformation) in the porta hepatis. Ultrasound is of limited value in visualizing the superior mesenteric vein or mesenteric circulation, but this limitation of ultrasound can be overcome with CT or MRI.

Bland thrombus in a contrast enhanced exam is hypodense on CT (Fig. 2A–C) and hypointense on MRI (Fig. 3). Once cavernous transformation is present, the main and often right and left portal veins are difficult to identify and are replaced by numerous enhancing collaterals in the porta hepatis (Fig. 2D).

Doppler ultrasound is generally the imaging method of choice for demonstrating collateral vessels, cavernoma, or areas with solid hyperechoic substance within the portal vein or a branching vein. The portal vein may be distended. Doppler imaging is of primary benefit when evaluating the presence and direction of blood flow within vessels. It can also

### Table 1. Risk factors for portal vein thrombosis and Budd-Chiari syndrome

| Risk factors                  | Associated conditions                  |
|------------------------------|---------------------------------------|
| Protein C deficiency         | Myeloproliferative disorders          |
| Factor V leiden              | Prior abdominal surgeries             |
| Protein S deficiency         | Postsurgical thrombosis               |
| Oral contraceptive use       | Cirrhosis                             |
| JAK2 mutation                | Neoplasm                              |
| Homocysteine                 | Pancreatitis                          |
| Antiphospholipid syndrome    | Inflammatory conditions of the abdomen|
| Antithrombin III deficiency  | Abdominal Infections (sepsis)         |
| Pregnancy                    | Ascites                               |
| Diaphragmatic compression    |                                       |
| Paroxysmal nocturnal         |                                       |
| hemoglobinuria               |                                       |

Fig. 1. Imaging characteristics of portal vein thrombosis. A, Grey scale ultrasound. Grey scale sonographic image demonstrates intraluminal echogenic material in the main portal vein, compatible with thrombus (yellow arrow); B, Power Doppler ultrasound. Power Doppler demonstrates thrombosis with lack of internal flow within the main portal vein (yellow arrow).
be used to detect partially occlusive thrombus formations, particularly those involving tumor invasion of vessels. However, endoscopic ultrasound is of limited value in visualizing the intrahepatic portion of the portal vein and the distal superior mesenteric vein or for evaluating thrombus that extends into the mesenteric circulation. CT scanning can distinguish between acute versus chronic disease. CT may also be used to determine the extent of obstruction or if a neoplastic process is involved. Surrounding vasculature may be assessed if the thrombus extends into the superior mesenteric vein or splenic vein.22

Treatment

When portal venous tumor thrombosis involves the first or second branch of the portal vein, hepatic resection with portal vein thrombectomy is usually the procedure of choice. Other treatment options include cisplatin and 5-fluorouracil hepatic chemotherapy infusion, but results are limited. Due to tumor recurrence rates, liver transplantation is often unsuccessful. The use of 3D conformal radiation therapy (3D-CRT) has also been reported, but the data are insufficient to recommend this for general use.23

Medical treatment of patients with PVT consists primarily of anticoagulation agents. The use of heparin has been recommended when rapid onset of anticoagulation is required and to bridge patients until oral anticoagulation therapy can begin. For this purpose, intravenous and subcutaneous heparin appear to be equally effective.24 In general, patients with identified prothrombotic conditions should be maintained on anticoagulation for life. For patients that further progress to acute PVT on anticoagulation, percutaneous thrombolysis can be considered but secondary complications

Fig. 2. Contrast-enhanced CT. A, Acute thrombosis of the umbilical segment of the left portal vein presenting as a hypodense filling defect (yellow arrow). Contrast opacification is seen proximally in the left portal vein (blue arrow); B, Acute thrombosis of the right portal vein presenting as a hypodense filling defect (yellow arrow) 2 months later in the same patient as Fig. 2A; C, Several months later in the same patient as Fig. 2A, thrombosis has propagated to the main portal vein and is similarly seen as a hypodense filling defect (yellow arrow). Incidentally, there is a subacute hematoma anteriorly after a liver biopsy; D, Follow-up CT 1 year later demonstrates cavernous transformation of the portal vein. Numerous tortuous venous collaterals have replaced the chronically thrombosed portal vein (yellow arrow).

Fig. 3. Contrast-enhanced T1-weighted MRI. A fat-suppressed, volumetric interpolated breath hold examination (VIBE) MRI image in the same patient as Fig. 2A, demonstrates a hypointense filling defect in the left portal vein (yellow arrow) consistent with acute thrombosis.
may develop.24 Although study populations to date have been small, the data have shown that anticoagulation is relatively safe and should be used as a first line treatment in patients with PVT and liver cirrhosis.25,26 Whether anticoagulation should be used in cases of liver cirrhosis has been controversial; and further investigations are warranted, particularly in the presence of comorbid conditions, such as esophageal varices and multiple coagulative disorders.14,25 One study estimated that partial to complete recanalization was achieved in approximately 60% of patients when anticoagulation was maintained with an international normalization ratio (INR) of 2.0 to 3.0. and an INR target of 2.5. Patients with thrombocytopenia with a platelet count less than 50 × 10^9/L may be at increased risk for bleeding complications.25 Some studies suggested that the overall balance between anticoagulant and procoagulant factors generally remained in proportion but were reduced in liver cirrhosis.27 There have been single subject case reports showing the possible benefit of factor Xa inhibitors in PVT, but large studies should to be conducted before these inhibitors are recommended for general clinical use.28–30

Patients with medical complications such as variceal bleeding, refractory ascites, portal hypertension, or continued thrombosis despite anticoagulation should be considered for transjugular intrahepatic portosystemic shunt (TIPS) procedure.28,31 One study suggested that the benefit of anticoagulation therapy was limited to patients who had initiation of anticoagulation within 10 months of disease manifestation and had confirmed diagnoses.32

**Budd-Chiari syndrome (BCS)**

BCS, or hepatic vein thrombosis, is a condition caused by obstruction of the venous blood outflow from the liver.4,33,34 This may involve one or more of the hepatic veins and may or may not involve the inferior vena cava.33 Blood flow obstruction from cardiac disorders and sinusoidal obstruction syndrome, a nonthrombotic disorder involving either the central hepatic veins or sinusoids secondary to injury of the sinusoidal wall, are not included in BCS. BCS is a rare vascular disorder of the liver with an estimated incidence of 0.1–0.8/1,000,000 per year and a prevalence of 1.4–2.4/1,000,000 per year in the US.1,34

**Presentation**

Patients with BCS typically present with abdominal pain, evidence of portal hypertension, hepatomegaly, and worsening liver function.3,4 Liver injury results from elevated intrahepatic pressure due to proximal thrombosis. Hepatic blood flow is unable to circumvent the blocked venous outflow.3 BCS appears histologically as areas of liver with centrilobular congestion and necrosis. In chronic cases, centrilobular fibrosis can develop. As with PVT, BCS can have a variable disease onset and clinical course (see Table 1).3

**Risk factors**

Risk factors associated with the development of BCS are hereditary protein C deficiency, antiphospholipid syndrome, and factor V Leiden.4,35 Among these, protein C deficiency appears to be most commonly associated with hepatic vein thrombosis.6 Single or multiple prothrombotic disorders as well as local components within the venous structures may contribute to the development of BCS.6 In a recent study, plasminogen activator inhibitor-1 (PAI-1) was found to be elevated in a subgroup of patients with BCS. It was suggested that increased levels of PAI-1 was related to fibrinolysis dysfunction in these patients.33 One case report found that use of oral contraceptives may be significant risk factor in patients with an underlying prothrombotic disorder.34

There is a growing body of evidence suggesting that patients with BCS should be screened for the JAK2V617F mutation.6,10 Since many patients with myeloproliferative disorders are not discovered with conventional medical techniques, this could be particularly helpful for patients with BCS with no known history of a myeloproliferative disorder.8 Recently, ethnic and geographic differences in the prevalence of JAK2V617F mutations in Western countries and in China were described. In Western countries, prothrombotic disorders are more likely to underlie BCS, whereas membranous obstruction appears to be a more prevalent cause in Asia, specifically China. Since the prevalence of BCS is lower in China than Western countries,11 the occurrence rates of the JAK2V617F mutations are lower as well. Therefore, JAK2V617F screening may not be indicated for patients with BCS in Asian countries. However, screening for this mutation may still be a useful tool in Western countries.11,13 Additionally, the 46/1 haplotype did appear to be an associative risk factor for JAK2V617F in BCS, but the low prevalence rate of this haplotype prevents it from being a cost-effective routine screen in Chinese patients.37,38

**Diagnosis**

Doppler ultrasound, MRI, and CT angiography are the most frequently used imaging techniques to assist in the diagnosis of BCS.2 Ultrasound in the acute stage can demonstrate hepatic vein thrombus as intraluminal hyperechogenicity with lack of color and spectral doppler flow. Secondary, less specific findings on ultrasound include gallbladder edema, pleural effusion, and ascites. Chronic cases may show porto-systemic collateral circulation and splenomegaly.39 Contrast enhanced CT (Fig. 4A and 4B) or MRI can demonstrate hypo-dense or hypointense filling defects in the hepatic veins, respectively. The use of CT and MRI may be a useful tool to distinguish BCS from liver cirrhosis through visualization of the caudate vein. Caudate vein dilatation and enhancement are due to intrahepatic collateral venous flow from other lobes. This was found by comparing MR images of BCS patients with control subjects. One study noted that 80% of patients with BCS had intrahepatic collateral veins.24 Furthermore, hypertrophy of the caudate lobe can compress the inferior vena cava (IVC). Typically, liver cirrhosis is associated with extrahepatic collateral venous circulation, whereas BCS may involve both extrahepatic and collateral intrahepatic circulations. The use of MRI may be a useful tool in distinguishing chronic BCS from liver cirrhosis by imaging the caudate vein.34

**Treatment**

There are a number of scoring indices that are predictive for the treatment of BCS. The Rotterdam Criteria appears to have the best discrimination index with respect to mortality over a 3 month period. This scale may be helpful in determining whether intervention is necessary.40,41 Similarly, the BCS TIPS prognostic index (PI) score demonstrates good accuracy with respect to mortality prediction. A relatively new scale, the BCS-intervention-free survival prognostic score (BCIS
Conclusions

The most common cause of obstructive venous disease of the liver is hypercoagulation. Symptoms are often nonspecific, with evidence of worsening liver function. Doppler ultrasound, CT, and MRI can be helpful in making diagnoses. Treatment efforts should focus on ameliorating the underlying condition. Anticoagulation is a therapeutic mainstay that can promote recanalization.

Conflict of interest

None

Author contributions

Writing the article (TPS), providing the radiographic images and interpretation for the manuscript (MM), conceiving the idea for the review and editing the manuscript (GYW).

References

[1] Qi X, Jia J, Ren W, Yang M, De Stefano V, Wang J, et al. Scientific Publications on Portal Vein Thrombosis and Budd-Chiari Syndrome: a Global Survey of the Literature. J Gastrointestin Liver Dis 2014;23:65–71.
[2] Sogaard KK, Astrup LB, Vilstrup H, Gronbaek H. Portal Vein Thrombosis: risk factors, clinical presentation and treatment. BMC Gastroenterol 2007;7:34. doi: 10.1186/1471-230X-7-34.
[3] Kumar V, Abbas AK, Fausto N, Aster JC. Robbins and Cotran Pathologic Basis of Disease. Philadelphia: Saunders Elsevier, 2010.
[4] Janssen HL, Meinardi JR, Vleggaar FP, van Uum SH, Haagsma EB, van der Meer FJ, et al. Factor V Leiden Mutation, prothrombin gene mutation, and deficiencies in coagulation inhibitors associated with Budd-Chiari Syndrome and portal vein thrombosis: results of a case-control study. Blood 2000;96:2364–2368.
[5] Parikh S, Shah R, Kapoor P. Portal Vein Thrombosis. Am J Med 2010;123:111–119. doi: 10.1016/j.amjmed.2009.05.023.
[6] Denninger MH, Chait Y, Casadevall N, Hillaire S, Guillin MC, Bezaud A, et al. Cause of Portal or Hepatic Venous Thrombosis in Adults: The Role of Multiple Concurrent Factors. Hepatology 2010;42:119–128.
[7] Qi X, Ren W, De Stefano V, Fan D. Associations of Coagulation Factor V Leiden and Prothrombin G20210A Mutations With Budd-Chiari Syndrome and Portal Vein Thrombosis: A Systematic Review and Meta-analysis. Clin Gastroenterol Hepatol 2014;12:1801–1812.e7. doi: 10.1016/j.cgh.2014.04.026.
[8] Patel RK, Lea NC, Heneghan MA, Westwood NB, Milojkovic D, Thanigaikumar M, et al. Prevalence of the Activating JAK2 Tyrosine Kinase Mutation V617F in the Budd-Chiari Syndrome. Gastroenterology 2006;130:2031–2038. doi: 10.1053/j.gastro.2006.04.008.
[9] Goulding C, Ullenthal B, Foroni L, Duke V, Traore A, Kottaridis P, et al. The JAK2V617F tyrosine kinase mutation identifies clinically latent myeloproliferative disorders in patients presenting with hepatic or portal vein thrombosis. Int J Lab Hematol 2008;30:415–419. doi: 10.1111/j.1751-553X.2007.00973.x.
[10] Smallberg JH, Koehler E, Murad SD, Plessier A, Seijo S, Trehicka J, et al. The JAK2 46/1 Haplotype in Budd-Chiari Syndrome and Portal Vein Thrombosis. Blood 2011;117:3968–3973. doi: 10.1182/blood-2010-11-319087.
Delgado MG, Sijo S, Yepes I, Achecar L, Catalina MV, García-Criado A, Hall TC, Garcea G, Metcalfe M, Bilku D, Dennison AR. Management of Acute Portal Vein Thrombosis in liver cirrhosis: A systematic review and meta-analysis of observational studies. Eur J Gastroenterol Hepatol 2015;27:77–83. doi: 10.1097/MEG.0000000000000221.

Dentali F, Squizzato A, Brivio L, Appio L, Campiotti L, Crowther M, Donglei Z, Jianyu H, Ning Y. Protein C and D-dimer are related to portal vein thrombosis in patients with liver cirrhosis. J Hepatol 2010;52:404–411. doi: 10.1016/j.jhep.2009.09.0591.x.

Qi X, Chen H, Han G. Effect of antithrombin, protein C and protein S on portal vein thrombosis in liver cirrhosis: a meta-analysis. Am J Med Sci 2013;346: 243–254. doi: 10.1097/MAJ.0b013e3182971e4a.

Chen H, Qi X, He C, Yin Z, Fan D, Han G. Coagulation imbalance may not contribute to the development of portal vein thrombosis in patients with cirrhosis. Thromb Res 2013;131:173–177. doi: 10.1016/j.thromres.2012.11.003.

Tang W, Wang Y, Zhao X, Wang X, Zhang T, Oo X, et al. Procoagulant imbalance aggravated with falling liver function reserve, but not associated with the presence of portal vein thrombosis in cirrhosis. Eur J Gastroenterol Hepatol 2015;27:672–678. doi: 10.1097/MEG.0000000000000352.

Plessier A, Sablon N, Consigny Y, Hakan, Zappa M, Denninger MH, et al. Aiming at Minimal Invasiveness as a Therapeutic Strategy for Budd-Chiari Syndrome. Hepatology 2006;44:1308–1316. doi: 10.1002/hep.21354.

Ponziani FR, Zocca MO, Campanile C, Rinninella E, Tortora A, Di Maurizio L, et al. Portal Vein Thrombosis: Insight into pathophysiology, diagnosis, and treatment. World J Gastroenterol 2010;16:143–155. doi: 10.3748/wjg.v16.i2.143.

Attali J, Huerque A, Loock M, Thiefin G, Marcus C, Long A. Computed tomography follow-up of acute portal vein thrombosis. Diagnostic and Interventional Imaging, 2014;95:579–585. doi: 10.1016/j.dii.2014.02.018.

Qi X, Han G, He C, Yin Z, Guo W, Niu J, et al. CT features of non-malignant portal vein thrombosis: a pictorial review. Clin Res Hepatol Gastroenterol 2012;36:561–568. doi: 10.1016/j.clinre.2012.05.021.

Tanaka Y, Nakaawa T, Komori S, Hidaka H, Okuzaki Y, Takada J, et al. Radiotherapy for patients with unresectable advanced hepatocellular carcinoma with invasion to infrarenal large vessels: Efficacy and outcomes. J Gastroenterol Hepatol 2014;29:352–357. doi: 10.1111/jgh.12333.

Hall TC, Garcia G, Metcalf M, Bilkis D, Dennison AR. Management of Acute Non-cirrhotic and Non-malignant Portal Vein Thrombosis: A Systematic Review. World J Surg 2011;35:2510–2520. doi: 10.1007/s00268-011-1198-0.

Dagdag MG, Sijo S, Yepes I, Ashcer L, Catalina MV, Garcia-Criado A, et al. Efficacy and Safety of Anticoagulation on Patients With Cirrhosis and Portal Vein Thrombosis. Clin Gastroenterol Hepatol 2012;10:776–783. doi: 10.1016/j.cgh.2012.01.012.

Chung JW, Kim GH, Lee JH, Oh KS, Kang ES, Jeong SH, et al. Safety, efficacy, and response predictors of anticoagulation for the treatment of nonmalignant portal vein thrombosis in patients with cirrhosis: a propensity score matching analysis. Clin Mol Hepatol 2014;20:384–391. doi: 10.3350/cmh.2014.20.2.

Qi X, De Stefano V, Li H, Dai J, Guo X, Fan D. Anticoagulation for the treatment of portal vein thrombosis in liver cirrhosis: A systematic review and meta-analysis of observational studies. Eur J Intern Med 2015;26:23–29. doi: 10.1016/j.ejim.2014.12.002.

Martinez M, Tandra A, Vuppalanchi R. Treatment of Acute Portal Vein Thrombosis by Nontraditional Anticoagulation. Hepatology 2014;60:425–426. doi: 10.1002/hep.26999.

Ponnath S, Babatz J, Beyer-Westendorf J. Successful treatment of acute portal vein thrombosis with rivaroxaban. Thromb Haemost 2011;10:626–627. doi: 10.1160/TH11-05-0407.

Lenz K, Dieplinger B, Buder R, Pringer P, Rauch M, Voglmayr M. Successful treatment of partial portal vein thrombosis (PVT) with low dose rivaroxaban. J Gastroenterol 2014;52:1175–1177. doi: 10.1007/s00334-1385171.

Luca A, Miraglia R, Caruso S, Milazzo M, Sapere C, Maruzzelli L, et al. Short- and long-term effects of the transjugular intrahepatic portosystemic shunt on portal vein thrombosis and cirrhosis. Gut 2011;60:846–852. doi: 10.1136/gut.2010.220803.

Senzolo M, Sartori T, Rossetto V, Burra P, Cillo U, Bocagni P, et al. Prospective evaluation of anticoagulation and transjugular intrahepatic portosystemic shunt for the management of portal vein thrombosis in cirrhosis. Liver Int 2012;32:919–927. doi: 10.1111/j.1478-3231.2012.02785.x.

Hoekstra J, Guimaraes AH, Leebeeck FW, Murad SD, Malffiet JM, Plessier A, et al. Impaired fibrinolysis and JAK2V617F mutation for the early diagnosis of Ph-myeloproliferative neoplasms in patients with venous thromboembolism: a meta-analysis. Blood 2009;115:5617–5623. doi: 10.1182/blood-2008-12-196014.

Amiratno L, Guardacone M, Brancaccio V, Margagnone M, Manguos F, Iannaccone L, et al. Risk Factors and clinical presentation of portal vein thrombosis in patients with liver cirrhosis. J Hepatol 2004;40:736–741. doi: 10.1016/j.jhep.2004.01.001.

Donglei Z, Jianyu H, Ning Y. Protein C and D-dimer are related to portal vein thrombosis in patients with liver cirrhosis. J Gastroenterol Hepatol 2010;25:116–121. doi: 10.1111/j.1440-1746.2009.05921.x.

Qi X, Chen H, Han G. Effect of antithrombin, protein C and protein S on portal vein thrombosis in liver cirrhosis: a meta-analysis. Am J Med Sci 2013;346: 243–254. doi: 10.1097/MAJ.0b013e3182971e4a.

Sabol T.P et al: Portal vein thrombosis and Budd-Chiari syndrome